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Abstract
MYD88 L265P mutation causes constitutive activation of NF-κB and possible driver mutation 
in B-cell lymphoid malignancies.  It is frequently detected in Waldenstrom’s macroglobulinemia 
（WM） （50％-100％）, and its detection is important in diagnostic and therapeutic targets of 
this syndrome.  Standard detection method of MYD88 L265P mutation in clinical practice 
has yet to be established.  We developed semi-nested PCR-based restriction fragment 
length polymorphism （snPCR-RFLP） to detect the mutation.  The snPCR-RFLP method is a 
modification of the PCR-RFLP method, which uses the restriction enzyme BsiEI that recognizes 
CGACT / CG, intending to increase detection sensitivity by amplification of mutated allele in 
the DNA sample using semi-nested PCR before enzyme digestion.  The detection sensitivity 
of snPCR-RFLP was estimated as 0.1％, by detecting mutated allele in wild-type allele in the 
cloned plasmid DNA, which is comparable with allele-specific （AS） PCR method widely used 
as sensitive detection method.  By analyzing 40 cases with IgM monoclonal gammopathy, 
snPCR-RFLP detected 29/40 （70％） of all cases, 22 / 31 （70.9％） of WM, and 6/9 （66.6%） 
of IgM-type monoclonal gammopathy with undetermined significance （IgMMGUS）, including five 
cases （three cases of WM and two cases of IgMMGUS） in which the mutation was detected 
only by snPCR-RFLP but not by Sanger sequencing method.  Regarding DNA sample status, 
particularly five cases, a case was extracted from formalin-fixed paraffin-embedded tissue and 
four cases were extracted from cells by Ficoll-Hypaque density gradient.  In correlation with 
clinical features, the MYD88 mutation detected by snPCR-RFLP method was associated with 
the adverse prognostic index （WMIPSS） of WM using patient age, hemoglobin （Hb） level, 
platelet count, β2MG level, and serum IgM level （p＝0.055）.  The snPCR-RFLP method 
is a clinically useful MYD88 mutation detection method that can be performed in general 
laboratories.
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Introduction
　Since myeloid differentiation primary response 
88 （MYD88） L265P mutation was reported as a 
commonly recurring mutation in Waldenstrom’s 
macroglobulinemia （WM） in 20121, the importance 
of this particular mutation has been confirmed in 
several types of B-cell lymphoid tumors, including 
lymphoplasmacytic lymphoma （LPL）/ WM and 
diffuse2 large B-cell lymphoma with involvement of 
extranodal sites, such as the central nervous system 
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and leg1, 3.  Particularly, in WM, MYD88 L265P 
mutation has been found in ＞90％ of cases and is 
an important prognostic and therapeutic biomarker in 
this clinical syndrome4.
　A number of methods for MYD88 L265P 
detection have been reported.  These include Sanger 
sequencing1, allele-specific PCR （AS-PCR） with or 
without real-time PCR5-7, polymerase chain reaction-
restriction fragment length polymorphism （PCR-
RFLP）2, high-resolution melting analysis8, and 
droplet digital PCR9.  These methods have detection 
sensitivities of approximately 0.005％-5％.  However, 
standardized methods for routine practice have yet 
to be established.  Unresolved issues include 1） the 
requirement for specific equipment and 2） a tenfold 
difference in detection sensitivity among study groups 
in AS-PCR5, 7.
　Detection is also affected by DNA sample 
preparation.  If DNA extracted from CD19-sorted 
B cells, PCR-based RFLP can detect 91.7％ of cases 
of WM10.  However, in practice, DNA can only 
be obtained from formalin-fixed paraffin-embedded 
（FFPE） tissues, such as bone marrow, because the 
diagnosis of WM is still based on the infiltration 
of lymphoplasmacytoid cells in addition to IgM 
monoclonal gammopathy11.
　In the present study, we report a snPCR-RFLP 
method, a modification of PCR-based RFLP, for the 
detection of MYD88 L265P mutation ［8］.
　The present study aimed to establish a method for 
the detection of MYD88 L265P mutation, which is 
1） sensitive, 2） applicable to any source of DNA in 
clinical settings, and 3） feasible for general laboratories 
in hospitals, without requiring special equipment.
Materials and methods
1. Patients
　In 1984-2016, at Showa University Hospital, 40 
patients subjected to serum monoclonal IgM detection 
were selected for the present study.  According to the 
recommendations from the Second International
　Diagnosed with WM and nine patients were 
diagnosed with IgM monoclonal gammopathy 
of undetermined significance （MGUS）11.  The 
histopathological diagnosis of WM was based on 
evident infiltration of atypical lymphoid cells in the 
bone marrow.
　This study was approved by Showa University, 
Human Genome, Gene Analysis Research Ethics 
Committee （No.189）.  Informed consent was obtained 
from all participants or substitutes for participants of 
the study.
2. Semi-nested PCR-based RFLP （snPCR-RFLP）
　Genomic DNA was extracted using the QuickGene-
AutoS DNA Tissue Kit （FUJIFILM Wako Pure 
Chemical Corporation, Osaka, Japan） from unselected 
mononuclear cells isolated using a Ficoll-Hypaque 
density gradient of bone marrow cells in 33 cases.  In 
seven cases, genomic DNA was obtained from FFPE 
bone marrow tissues using DNA Isolator PS-rapid 
Reagent （FUJIFILM Wako）.  Paraffin-embedded 
decalcified bone marrow trephine biopsy specimens 
were excluded.
　To enable sufficient PCR amplification, we performed 
a snPCR before enzyme digestion.  In the first 
PCR, 100 ng of genomic DNA was amplified in a 
total volume of 50 µl, including 0.5 µl of Taq DNA 
polymerase （5 µ/µl）, 5 µl of 10×PCR-Buffer, and 1.0
µl of dNTPs obtained from the Taq DNA polymerase 
dNTPack （Roche Applied Science, Mannheim, Germany）, 
with the primers 5′-TTAGATGGGGGATGGCTGTTG-3′ 
（F1） and 5′-GCGAGTCCAGAACCAAGATTTG-3′ 
（R1）, yielding a 229-bp product （NG016964）.  The 
product obtained by the first PCR was purified using 
a QIAquick PCR Purification Kit （Qiagen, Hilden, 
Germany）.  After purification, 2 µl of eluate was 
subjected to a second PCR using the primers F1 
and 5′-ACCTCAGGATGCTGGGGAACTC-3′ （R2）, 
which produced a 179-bp product.  PCR conditions 
were initial denaturation at 94℃ for 5 min, 30 cycles 
of denaturation at 94℃ for 30 s, annealing at 57.5℃ 
for the first PCR and 57.2℃ for the second PCR for 
1 min, and elongation at 72.0℃ for 2 min, followed 
by a final extension step at 72℃ for 7 min.  After 
the second snPCR, 10 µl of purified semi-nested PCR 
product was digested using 20 U of BsiEI （New England 
Biolabs, Tokyo, Japan） in a total volume of 20 µl for 
2 h, followed by separation by electrophoresis on a 5％ 
acrylamide gel.  After electrophoresis, the acrylamide 
gel was stained with SYBR Green Ⅰ （Takara Bio Inc., 
Shiga, Japan） for 60 min and visualized using a 254-
nm UV trans-illuminator.  MYD88 L265P mutant alleles 
were digested into 125- and 48-bp fragments, which were 
visualized on acrylamide gel.
　In snPCR-RFLP analysis, to exclude false positive 
results from repeated PCR, we performed first PCR 
to acrylamide gel analysis including plasmid DNA 
（10 ng） with or without mutation and genomic DNA 
obtained from patients.
In cases in which 100 ng of genomic DNA was 
unavailable for the first PCR, at least 5 ng of DNA 
was used for this step, following the same protocol 
described above.
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3. Determination of the detection sensitivity of snPCR-
RFLP
　A 418-bp DNA fragment that contained either 
c.794T or c.794C （NM 002468） was obtained by PCR 
（forward primer, 5′-GAAGATCTCTGCACACCTGA-3′; 
reverse primer, 5′-GATTCCTCCTACAACGAAAG-3′） 
using DNA extracted from bone marrow cells of 
a patient diagnosed with WM with the MYD88 
L265P mutation （lane 6）.  Either the wild-type allele 
or mutant allele was cloned into the pGEMⓇ-T 
Vector （Promega, Madison, WI, USA）, and plasmids 
were used as MYD88 L265P-positive （mutant） and 
negative control （wild type）.
　The sensitivity of snPCR-RFLP was determined by 
serial dilution of the mutant plasmid with the wild-type 
plasmid （Fig. 1）.  In detail, 10 ng pGEMⓇ-T vector 
with the cloned MYD88 L265P allele was serially 
diluted with those with the wild-type allele to 10％, 
5％, 2.5％, 1％, 0.5％, 0.25％, and 0.1％.  To determine 
the detection sensitivity of snPCR-RFLP analysis, 
approximately 10 ng of the plasmid DNA with various 
percentages of mutant allele was used as template DNA 
and analyzed by snPCR-RFLP protocol described in the 
Materials and Methods section （Fig. 1）.
4. DNA sequencing
　We performed Sanger method to determine the 
corresponding nucleotide substitution.  The PCR 
product （229 bp） obtained by the primers for the 
first PCR （F1 / R1） was purified by 1.0％ agarose 
gel electrophoresis.  Both strands of the products 
were sequenced with the PCR primers using a 
BigDye Termination v1.1 Cycle Sequencing Kit （Life 
Technologies Japan, Ltd., Tokyo, Japan） and analyzed 
using an ABI PRISM 310 Genetic Analyzer （Applied 
Biosystems, Foster City, CA, USA）.
5. Correlations between clinical parameters and 
genotype and statistical analyses
　Pretreatment data were extracted from the patient’s 
medical records and hospital’s computerized databases. 
Splenomegaly was evaluated by abdominal computed 
tomography findings at diagnosis.
　The Mann-Whitney U test was performed to 
compare clinical values between cohorts with or 
without MYD88 L265P mutation.  Fisher’s exact test 
was used to evaluate differences in clinical features, 
such as karyotype, splenomegaly, and FFPE samples, 
between patients with or without MYD88 L265P 
mutation.
　In the statistical analysis of the International 
Prognostic Scoring System of WM （IPSSWM）12 
and the revised IPSSWM （rIPSSWM）13, the sum of 
scores for adverse prognostic markers was compared 
between patients with or without MYD88 L265P 
mutation.
　All analyses were performed with two-sided tests 
at a significance level of 0.05 using JMP 15 （SAS 
Institute Inc., Cary, NC, USA）.
Fig. 1.   Detection sensitivity analysis of snPCR-based RFLP for MYD88 
L265P mutation
Plasmid DNA with the MYD88 L265P mutant allele was mixed with 
those carrying the wild-type MYD88 allele at the indicated percentage. 
The mixed plasmid DNA was subjected to snPCR-based RFLP as 
described in the Materials and Methods section.  In this experiment, 
we considered that as low as 0.1％ of the MYD88 L265P mutant 
allele was detectable in the examined DNA samples by performing this 
snPCR-based RFLP analysis.
Lane 1: 100 bp ladder; Lane 2: ddw; Lanes 3-10: 100％, 10％, 5％, 
2.5％, 1％, 0.5％, 0.25％, and 0.1％ mutant allele in wild-type allele, 
respectively.
173 bp band indicates wild-type allele of MYD88 gene, while 125 bp and 
48 bp band indicate mutant allele of MYD88 gene in samples.
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Fig. 2.  Bone marrow DNA analysis of patients with IgM monoclonal gammopathy
Genomic bone marrow DNA was subjected to snPCR-based RFLP as described in the Materials 
and Methods section.
A：Lane 1: 100 bp ladder. Lane 2: ddw. Lane 3: Plasmid DNA with wild-type MYD88 allele. Lane 
4: Plasmid DNA with mutant MYD88 allele. Clinical diagnoses were as follows: lanes 5–31, 41, 
and 42: Waldenstrom macroglobulinemia; lanes 32-40: IgM MGUS.
Out of 40 cases analyzed by snPCR-RFLP, results of acrylamide gel analysis of 38 cases 
were shown.
By visualizing the SYBR Green-stained acrylamide gel, MYD88 L265P mutated allele was 
judged to be present in lanes 6-10, 12-20, 23, 25, 26, 29, 30, 32, 36-42, but not in lanes 5, 
11, 21, 22, 24, 27, 28, 31, 33, 34, and 35.
Lanes 20, 21, 26, 31, and 40 were FFPE samples. Lanes 13, 14, 15, 22, and 30 were 
samples with DNA concentrations less than 100 ng for analysis.
Samples in lanes 26, 29, 32, 39, and 41 were judged to contain MYD88 L265P mutant allele 
by snPCR-RFLP, but not by Sanger sequencing.
B：Sanger sequence results showing the MYD88 gene with wild-type and L265P mutant alleles, 
corresponding to lanes 5 and 6, respectively.
C：Sanger sequence of five samples （lanes 26, 29, 32, 39, and 41） carrying MYD88 wild-type 
allele, while the mutant allele was detected in these by snPCR-RFLP, as shown in Fig. 2（A）.




1. snPCR-RFLP and sensitivity
　As shown in Fig. 2（A）, plasmid DNA of MYD88 
wild type （lanes 3） and plasmid DNA of MYD88 
L265P （lanes 4） were analyzed by snPCR-RFLP. 
Samples with MYD88 wild type produced a 173-
bp product by SNPCR, whereas those with MYD88 
L265P produced 125- and 48-bp fragments.
　As determined by the serial dilution of mutant 
plasmid DNA　in wild-type plasmid, the sensitivity 
was at least 0.1% mutant allele （Fig. 1）.
2. Analysis of the MYD88 L265P mutation
　As shown in Fig. 2（A）, in 38 examined cases, we 
were able to detect the mutant allele by observation 
of a 125-bp band with or without a 48-bp band in 
SYBR Green stained-acrylamide gel analysis.
　We detected MYD88 L265P mutation using snPCR-
RFLP method in 28 of 40 patients.
　Table 1 shows the results of detection of MYD88 
L265P mutation in the present study, with respect 
to the clinical diagnosis and analyzed DNA sample 
status.  Compared with Sanger sequencing method, 
snPCR-RFLP showed higher detection rate of this 
mutation irrespective of clinical diagnosis, showing 
70％ （28 / 40） vs 57.5％ （23 / 40） in IgM monoclonal 
gammopathy, 61.2％ （19 / 31） vs 70.9％ （22 / 31） 
in WM, and 44.4％ （4 / 9） vs 66.6％ （6 / 9） in 
IgMMGUS.  Regarding DNA sample status, in both 
DNA extracted from Ficoll-Paque density gradient 
method and FFPE, snPCR-RFLP showed higher 
detection rate of this mutation compared with the 
Sanger method, showing 57.5％ in the Sanger method 
and 69.6％ in snPCR-RFLP and 57.1％ in Sanger 
method and 71.4％ in snPCR-RFLP, respectively.
　In Figure 2（B）, typical Sanger sequencing results 
for the absence and presence of c.794T＞C are shown 
in lanes 5 and 6, respectively.  In five cases, Sanger 
sequencing failed to detect mutant nucleotides, while 
snPCR-RFLP showed a 125-bp band, suggesting the 
presence of a mutant allele （Fig. 2（A）（C））.
　In snPCR-RFLP, sample preparation, such as the 
preparation of DNA from FFPE sections, did not 
influence the detection of MYD88 L265P mutation 
（Table 2）.
3. MYD88 L265P mutation and clinical parameters
　The relationships between MYD88 L265P mutation 
and clinical parameters were analyzed in patients with 
Table 1.   Detection of MYD88L265P mutation in IgM monoclonal gammopathy by Sanger sequencing 
method and snPCR-RFLP
Clinical diagnosis / sample status /％  
of mutation detected 
Sanger method result snPCR-RFLP method result
L265P-detcted L265P-undetected
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IgMMGUS （n＝9） and patients with WM （n＝31）. 
In the IgMMGUS cohort, none of the clinical indices 
were significantly related to MYD88 L265P mutation. 
These indices included age, sex, serum IgM level, 
white blood cell count, Hb level, platelet count, serum 
albumin level, lactate dehydrogenase （LDH） level, 
β2-microglobulin （β2MG） level, soluble interleukin-2 
receptor （sIL2R） level, abnormal karyotype, and 
splenomegaly.  In the WM cohort, MYD88 L265P 
mutation was slightly related to an increase in LDH 
（p＝0.06） or sILR （p＝0.07）.  In both cohorts, 
abnormal karyotypes and splenomegaly were not 
significantly associated with MYD88 L265P mutation 
（Table 2）.
　To evaluate the prognostic relevance of MYD88 
L265P mutation in WM, we studied the relationship 
between mutation and IPSSWM or rIPSSWM, which 
are established prognostic indices of WM.  IPSSWM, 
but not rIPSSWM, tended to be associated with 
MYD88 L265P mutation in WM （Table 2）.
Discussion
　In the present study, we showed that snPCR-
RFLP is sensitive and feasible method that does not 
require special equipment to detect MYD88 L265P 
mutation in clinical setting, such as IgM monoclonal 
gammopathy, in which MYD88 L265P mutation needs 
to be studied.  snPCR-RFLP for MYD88 L265P 
mutation is widely applicable in various DNA samples 
in terms of difference in its extracted method and 
quality.  It is the first study that describes the results, 
applying snPCR-RFLP method for MYD88 L265P 
detection in IgM monoclonal gammopathy.
　In the detection of MYD88 L265P mutation, a 
number of methods of analysis has been reported 
with a wide range of difference in their detection 
sensitivity, showing 10％ in Sanger sequencing 
method2 to 0.0035％ in ddPCR method9.  The 
detection sensitivity of snPCR-RFLP （0.1％） estimated 
in the present study is comparable with 0.5％-0.1％ 
Table 2.   Clinical characteristics of IgM monoclonal gammopathy stratified by MYD88L265P mutation status detected by 
snPCR-RFLP
IgM MGUS Waldenstrom’s macroglobulinemia
MYD88 Wild type（n＝3） L265P（n＝6） p-value Wild type （n＝9） L265P（n＝22） p-value
Age 65（48-77） 67（36-87） 0.69 73（34-88） 69（40-86） 0.69
Sex 
（female / male） 2 / 1 2 / 4 0.86 5 / 4 5 / 17 0.1
IgM（mg/dl） 896（287-1,527） 1,114（552-1,744） 0.51 2,729（1,123-5,862） 3,341（402-6,438） 0.67
WBC（/mm3） 8,700（5,800-13,100）8,280（5,600-9,800） 0.89 4,000（3,500-15,200）5,350（2,000-8,600） 1.00
Hb（g/dl） 13.5（10.9-14.8） 10.8（7.6-14.5） 0.15 10.5（4.9-14.5） 9.4（4.4-13.2） 0.32
PLT（/mm3） 27.6（18.9-41.8） 23.4（0.3-41.7） 0.69 23.2（5.7-39.1） 17.6（3.2-41.7） 0.42
ALB（g/dl） 3.1（1.1-4.1） 3.3（1.2-4.6） 0.60 2.7（1.3-4.3） 3.0（1.2-4.2） 0.44
LDH（U/l） 195（127-249） 259（169-422） 0.51 228（143-403） 171（85-1,804） 0.06
β2MG（mg/l） 2.5（2.5-2.5） 4.2（1.7-8.9） 0.72 4.3（0.1-19.9） 3.4（2.4-6.0） 0.87
sIL2R（U/ml） 446（446-446） 455（288-581） 1.00 1,910（434-7,612） 3,504（697-16,750） 0.07
Abnormal 
karyotype
1 1 0.70 11 10 1.00
Splenomegaly 1 0 ND 5 10 0.70
IPSSWM 2（1-3） 3（1-4） 0.055
rIPSSWM 2（1-5） 2（1-4） 0.87
Statistical analysis of clinical data was performed using Mann-Whitney U test. Fisher’s exact test was performed on the 
difference in clinical values in sex, karyotype, splenomegaly, or FFPE between with or without MYD88L265P mutation. In 
analysis of IPSSWM, age, Hb level, platelet count, and β2MG and serum IgM levels were considered adverse prognostic 
factors. In rIPSSWM, age, and β2MG, LDH, and serum albumin levels were considered adverse prognostic factors.
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in PCR-RFLP2 or 1.5％-0.1％ in AS-PCR5, 7, of which 
the latter is an analytical method widely used for 
detection of MYD88 L265P mutation.  However, 
regarding detection sensitivity between analytical 
methods reported by different study groups, we need 
to be careful to compare their estimates, because 
these were derived from different methods, such as a 
group calculated them using genomic DNA obtained 
from patients with or without its mutation2 and the 
other using DNA from cell line with its heterozygous 
mutation or wild type7.  To more objectively estimate 
detection sensitivity, we employed plasmid DNA with 
wild-type and mutant allele.
　We found a difference in detection rate between 
the Sanger method （57.5％） and snPCR-RFLP 
（70％）.  It is because PCR products obtained after 
snPCR contained a higher number of amplified 
mutated alleles compared with those after the first 
PCR by PCR primers （F1 and R1 in the Materials 
and Methods section）, which was subjected to the 
Sanger method using cell cycle sequencing kit.
　MYD88 L265P mutation has been reported in 
＞90％ of WM cases.  Our estimate of 70.9％ in WM 
was apparently lower than previous estimates.  This is 
not likely due to an insufficient detection sensitivity 
（％ of mutant allele） of snPCR-RFLP because the 
observed sensitivity of 0.1％ is comparable to those of 
previously established, highly sensitive methods, such 
as AS-PCR, in which the MYD88 L265P mutation 
has been detected in 100％ of WM ［5］.  The lower 
mutation frequency in WM in the present study 
compared with previous estimates can be explained 
by 1） a difference in methods for the collection of 
lymphoid cells for the mutation analysis and 2） a 
difference in the patient selection.
　In CD19-sorted B cells, using PCR-RFLP, Argentou 
detected MYD88 L265P mutation in 91.7％ of 
patients with WM10.  In the present analysis, genomic 
DNA was obtained from unsorted bone marrow 
mononuclear cells, including both mononuclear cells 
isolated by Ficoll-Paque density gradient （33 patients） 
and cells in FFPE bone marrow tissues （7 patients）. 
The purity of clonally mutated cells in samples may 
affect the present results.
　Another explanation for the difference is our use 
of reported consensus criteria for the diagnosis of 
WM or IgM-MGUS, which is widely used in previous 
studies5.  However, the particular diagnostic criteria 
for this disease are somewhat ambiguous, with 
disagreements.  The criteria include the “unequivocal 
bone marrow infiltration of LPL with morphological 
evidence” for the diagnosis of WM.  However, the 
Mayo Clinic group reported that ＞10％ of LPL cells 
in the bone marrow are required in the diagnosis 
of WM14.  In the present study, we diagnosed a 
patient with WM if the atypical lymphoid cells of 
any grade were detected histopathologically.  As a 
result, the number of clonal B cells in the samples 
may be smaller than those in previous studies2, 15. 
This explanation is supported by our results for 
IgMMGUS; although the number of cases was 
small, the frequency of MYD88 L265P mutation 
（66.6％） was comparable to that in previous studies 
（47％-60％）16, 17.
　Calpaldi et al. also reported that MYD88 L265P 
mutation could be detected in samples obtained from 
decalcified BM biopsy containing ＜10% lymphoid 
cells with the differential diagnosis of low-grade B-cell 
lymphoma, including LPL / WM, essentially based on 
the recognition of lymphoma cells by the pathologist, 
irrespective of the percentage of cells in the bone 
marrow.
　In the present study, we found a relationship 
between the mutant allele and increase in serum 
LDH and sIL2R levels, which are biological markers 
of lymphoid proliferation.  Moreover, we found that 
these mutations tended to be associated with adverse 
prognostic scores in the IPSSWM.  This is apparently 
contradictory to recent findings, suggesting that the 
presence of MYD88 L265P mutation is associated 
with a favorable prognosis in WM4, 18.
　A potential explanation for this difference in the 
prognostic significance of the mutation is that the 
mutational analysis in the present study includes 
two groups with IgM monoclonal protein, one 
accompanied by evident clonal B-cell infiltration 
with MYD88 L265P mutation and the other lacking 
a sufficient number of clones.  We did not analyze 
the heterogeneity of WM based on the presence or 
absence of MYD88 L265P.
　Another explanation for the difference is that the 
significance of this mutation in Japanese patients 
with WM may differ from that in populations in 
Europe and the United States because all patients 
with relapsed or refractory WM carried this mutation 
in a clinical study on Japanese patients19.  To better 
understand the molecular basis of WM progression, 
additional analyses of gene mutations, such as 
mutations in CXCR4 and ARID1A, might be helpful4.
　Although MYD88 L265P mutation is defined as 
a driver mutation, present in ＞90％ of WM cases, 
its frequency ranges from 57％ to 100％ among 
studies3.  We believe that this relatively wide range of 
frequencies may be partially explained by unresolved 
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issues with respect to both diagnostic consensus and 
sample heterogeneity.  In this context, the present 
results emphasize the usefulness and limitations of the 
molecular diagnosis of clinical syndromes with IgM 
paraproteinemia due to MYD88 L265P mutation in 
clinical practice.
　The present results were obtained from retrospective 
and exploratory studies.  The number of patients was 
small and limited in the single institution.  DNA 
samples for mutation analysis were collected over a 
wide timespan （i.e., 1984-2016）, and the medications 
administered to patients varied.  Therefore, we did 
not analyze actual survival of patients with WM.
　Nonetheless, we believe that snPCR-RFLP is a 
useful screening method for the differential diagnosis 
of MYD88 L265P mutation-associated lymphoid 
disease in clinical settings.
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